Earlier this year, BMY completed a $14 billion acquisition of Karuna Therapeutics, gaining access to its experimental ...

Q3 2024 Earnings Call Transcript October 31, 2024 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...

Main Sequence has recruited three healthcare specialists and hopes to expand investments across therapeutics, diagnostics, ...

Two Key Executive Hires for Organizational Capabilities and GrowthCAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Anthos ...

The funding for Axonis, which is developing novel medicines for pain and epilepsy, reflects growing confidence in precision ...

Zai Lab has reported positive outcomes from its Phase III clinical trial of KarXT in China to treat schizophrenia.

BioSpace has been compiling a list of the most innovative and exciting biotechs for a decade. Here we take a look back at ...

Big-name venture capital firms are raising billions again, though funding a small number of de-risked companies. Meanwhile, ...

Metastasis remains the primary challenge to reducing cancer deaths worldwide. A new MSK study is providing unique insights ...

After the recent FDA approval for the promising schizophrenia drug Cobenfy (xanomeline and trospium chloride), Bristol Myers ...

Pharmaceutical giant AbbVie announced a deal to acquire biotech company Aliada Therapeutics, which is developing a potential ...